| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
7,660 |
6,314 |
$457K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
11,054 |
9,105 |
$353K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
1,394 |
1,112 |
$328K |
| 80053 |
Comprehensive metabolic panel |
6,218 |
4,907 |
$52K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
875 |
816 |
$51K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
6,613 |
5,114 |
$43K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
957 |
776 |
$27K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
961 |
893 |
$27K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,822 |
831 |
$19K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
559 |
498 |
$18K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
472 |
395 |
$13K |
| 81001 |
|
3,620 |
2,825 |
$10K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
1,184 |
891 |
$9K |
| 71045 |
Radiologic examination, chest; single view |
1,872 |
1,499 |
$8K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
202 |
178 |
$7K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
155 |
143 |
$7K |
| 81025 |
|
1,442 |
1,144 |
$4K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
102 |
94 |
$4K |
| 87634 |
|
67 |
60 |
$4K |
| 83735 |
|
724 |
575 |
$4K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
137 |
109 |
$4K |
| 80061 |
Lipid panel |
227 |
205 |
$3K |
| 84443 |
Thyroid stimulating hormone (TSH) |
188 |
178 |
$3K |
| 87071 |
|
627 |
574 |
$3K |
| 0002A |
|
86 |
85 |
$3K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
134 |
124 |
$2K |
| 0001A |
|
91 |
85 |
$2K |
| 84703 |
|
369 |
297 |
$2K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
238 |
176 |
$2K |
| 99222 |
Initial hospital care, per day, moderate complexity |
14 |
13 |
$1K |
| 74018 |
|
174 |
132 |
$1K |
| 70450 |
Computed tomography, head or brain; without contrast material |
14 |
12 |
$1K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
12 |
12 |
$1K |
| 81003 |
|
532 |
444 |
$1K |
| 84484 |
|
183 |
133 |
$1K |
| 86756 |
|
46 |
43 |
$797.58 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
91 |
86 |
$781.54 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
584 |
351 |
$735.95 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
66 |
59 |
$593.12 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
46 |
43 |
$561.40 |
| 71046 |
Radiologic examination, chest; 2 views |
72 |
68 |
$501.43 |
| 97597 |
|
82 |
25 |
$483.94 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
261 |
214 |
$314.24 |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
13 |
12 |
$301.63 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
551 |
486 |
$300.56 |
| 83880 |
|
12 |
12 |
$293.58 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
324 |
282 |
$251.20 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
12 |
12 |
$223.92 |
| 83690 |
|
27 |
26 |
$222.10 |
| 83605 |
|
36 |
25 |
$168.15 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
16 |
13 |
$55.52 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
19 |
14 |
$20.56 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
84 |
38 |
$8.60 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
27 |
26 |
$3.39 |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
155 |
143 |
$0.00 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
101 |
92 |
$0.00 |
| 36415 |
Collection of venous blood by venipuncture |
448 |
233 |
$0.00 |
| 99441 |
|
75 |
56 |
$0.00 |